Stock Events

Bionano Genomics 

$0.55
990
-$0.02-3.91% Friday 20:00

统计数据

当日最高
0.58
当日最低
0.52
52周最高
6.76
52周最低
0.52
成交量
3,114,955
平均成交量
1,425,795
市值
36.68M
市盈率
-0.1
股息收益率
-
股息
-

收益

8May已确认
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-1.24
-0.86
-0.49
-0.11
预期每股收益
-0.64
实际每股收益
-0.6

人们还关注

此列表基于关注BNGO的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。
Pacific Biosciences of California
PACB
市值373.13M
Pacific Biosciences提供长读取测序技术,与Bionano的光学基因组测序解决方案竞争,用于复杂的遗传研究和诊断。
Illumina
ILMN
市值16.63B
Illumina为基因分析提供测序和基于阵列的解决方案,直接与Bionano在基因组学市场竞争。
Thermo Fisher Scientific
TMO
市值211.09B
Thermo Fisher Scientific提供广泛的仪器和试剂用于基因组研究,包括下一代测序,与Bionano的基因组分析技术竞争。
Agenus
AGEN
市值351.74M
Agilent Technologies为整个实验室工作流程提供仪器、软件、服务和耗材,包括基因组研究,与Bionano的产品竞争。
Qiagen NV
QGEN
市值9.38B
Qiagen提供从样本到洞察力的解决方案,包括与Bionano的基因组分析解决方案竞争的下一代测序和分子诊断。
Intellia Therapeutics
NTLA
市值2.16B
Intellia Therapeutics参与CRISPR/Cas9基因组编辑技术,通过提供替代性的遗传研究和诊断方法,间接与Bionano的基因组测绘和分析技术竞争。
Editas Medicine
EDIT
市值384.05M
Editas Medicine在基因组编辑领域使用CRISPR技术,为Bionano的基因组分析和映射解决方案提供了有竞争力的替代方案。
CRISPR Therapeutics
CRSP
市值4.59B
CRISPR Therapeutics专注于利用CRISPR/Cas9技术开发基因药物,通过提供遗传研究的替代方法,间接与Bionano的基因组分析工具竞争。
Twist Bioscience
TWST
市值2.87B
Twist Bioscience 在合成生物学和基因组学领域开展业务,生产用于基因研究的合成DNA,与 Bionano 的基因组分析和测绘技术竞争。

分析师评级

4$平均价格目标
最高估值为 $6。
来自过去6个月内的 2 个评级。这不是投资建议。
买入
100%
持有
0%
卖出
0%

关于

Health Technology
Biotechnology
Professional, Scientific, and Technical Services
Testing Laboratories
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Show more...
首席执行官
R. Erik Holmlin
员工
344
国家
US
ISIN
US09075F1075
WKN
000A2JRLZ

上市公司